Emerging Drugs and Targets for Parkinson’s Disease

Affecting over 1.5 million people across the world, Parkinson’s disease is a progressive neurological condition characterized, in part, by the loss of dopaminergic neurons in the substantia nigra pars compacta. It affects 1.5% of the global population over 65 years of age. As life expectancy is increasing, over the next few years the number of patients with Parkinsons disease will grow exponentially. To date, there are no available treatments that are capable of curing Parkinsons disease, and the current goal of therapy, dopamine replacement strategies, is to reduce symptoms. After several years of disease progression, treatment is complicated by the onset of motor fluctuations and dyskinesias. This information reveals the great importance and social need of finding an effective therapeutic intervention for Parkinsons disease.

This exemplary new book reviews some of the most outstanding examples of new drugs currently in pharmaceutical development or new targets currently undergoing the validation process to try to reach the Parkinsons drug market in the next few years as potential disease modifying drugs. Providing up to date and comprehensive coverage, this book is essential reading for researchers working in academia and industry in any aspect of medicinal chemistry or drug discovery.